<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04219904</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0066</org_study_id>
    <secondary_id>NCI-2019-08255</secondary_id>
    <secondary_id>2017-0066</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04219904</nct_id>
  </id_info>
  <brief_title>PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer</brief_title>
  <official_title>Evaluation of Resectable Cervical Carcinoma With PET/MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well positron emission tomography/magnetic resonance imaging (PET/MRI)
      scan works in checking patients with stage IA1-IB3 cervical cancer that can be removed by
      surgery (resectable). PET/MRI scan may help doctors learn more about the spread of the
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To assess depth of cervical invasion with positron emission tomography/magnetic resonance
      imaging (PET/MRI) in patients with cervical cancer in clinical Federation of Gynecology and
      Obstetrics (FIGO) staging undergoing evaluation for surgical resection and correlate with
      pathology.

      SECONDARY OBJECTIVES:

      I. To correlate lymph node involvement on PET/MRI with pathology. II. To assess the
      inter-observer variability in the interpretation of PET/MRI. III. To correlate the
      quantitative imaging parameters of the tumor, such as the volumetric size, blood oxygen level
      dependent (BOLD), intravoxel incoherent motion (IVIM) analysis, apparent diffusion
      coefficient (ADC), diffusion tensor imaging (DTI), dynamic contrast-enhanced (DCE), metabolic
      tumor volume (MTV), total lesion glycolysis (TLG), standardized uptake value (SUV) and the
      glucose metabolic rate (GMR) with lymphovascular space invasion (LVSI) and tumor grade on
      surgical pathology.

      OUTLINE:

      Patients receive fludeoxyglucose F-18 and gadobutrol intravenously (IV) over 1 minute and
      undergo PET/MRI over 90-120 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of diagnosing depth of invasion on positron emission tomography/magnetic resonance imaging (PET/MRI)</measure>
    <time_frame>3 years</time_frame>
    <description>Both PET/MRI and pathology results will be dichotomized into binary outcomes and the accuracy of PET/MRI will assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing the Lymph node involvement by PET/MRI</measure>
    <time_frame>3 years</time_frame>
    <description>Will determine the relationship with pathology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-observer variability of PET/MR</measure>
    <time_frame>3 years</time_frame>
    <description>A PET report for clinical use will be generated by a radiologist with appropriate training and credentialing to read PET images. A separate MRI report for clinical use will be generated by a radiologist with appropriate training and credentialing to read MRI. Subsequently, PET/MR images will be evaluated by two radiologists who have appropriate training to read both PET and MRI and 2 research reports will be generated. Inter-observer variability of PET/MRI will be calculated using Cohen's kappa coefficient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative imaging parameters of the tumor</measure>
    <time_frame>3 years</time_frame>
    <description>Correlate the quantitative imaging parameters of the tumor, such as the volumetric size, blood oxygen level-dependent (BOLD), apparent diffusion coefficient (ADC), IVIM analysis, diffusion tensor imaging (DTI), dynamic contrast-enhanced (DCE), MTV, TLG, standardized uptake value (SUV) and GMR with LVSI and tumor grade on surgical pathology which serves as gold standard. Two-sample t-test or analysis of variance (ANOVA) will be used for comparing the group means between LVSI positive/negative groups and among tumor grades and types. Other statistical analysis will be carried out as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Stage IA Cervical Cancer</condition>
  <condition>Stage IA1 Cervical Cancer</condition>
  <condition>Stage IA2 Cervical Cancer</condition>
  <condition>Stage IB Cervical Cancer</condition>
  <condition>Stage IB1 Cervical Cancer</condition>
  <condition>Stage IB2 Cervical Cancer</condition>
  <condition>Stage IB3 Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (PET/MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludeoxyglucose F-18 and gadobutrol IV over 1 minute and undergo PET/MRI over 90-120 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (PET/MRI)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
    <other_name>Fludeoxyglucose (18F)</other_name>
    <other_name>fludeoxyglucose F 18</other_name>
    <other_name>Fludeoxyglucose F18</other_name>
    <other_name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (PET/MRI)</arm_group_label>
    <other_name>BAY86-4875</other_name>
    <other_name>Gadavist</other_name>
    <other_name>Gadograf</other_name>
    <other_name>Gadovist</other_name>
    <other_name>Protovis</other_name>
    <other_name>ZK 135079</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic (PET/MRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>nuclear magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic (PET/MRI)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with suspected clinical stage IA1-IB3 cervical cancer except patients
             with tumors &gt; 4 cm

          -  No contraindications to MRI

          -  Patients undergoing surgical procedure at MD Anderson

          -  Suspected cervical cancer

        Exclusion Criteria:

          -  Patients who have contraindication to MRI

          -  Glomerular filtration rate (GFR) &lt; 30

          -  Pregnant patients

          -  Patients with history of previous radiation

          -  Patients with previous surgery for cervical cancer, unless residual tumor noted on
             physical exam

          -  Patients with endometrial cancer extending to the cervix

          -  Allergic reaction to gadolinium based contrast

          -  Body weight of greater than 450 (181.4 kg)

          -  Patients requiring general sedation

          -  Extremely claustrophobic patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanaz Javadi</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanaz Javadi</last_name>
    <phone>713-563-7665</phone>
    <email>sanaz.javadi@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanaz Javadi</last_name>
      <phone>713-563-7665</phone>
    </contact>
    <investigator>
      <last_name>Sanaz Javadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>January 4, 2020</last_update_submitted>
  <last_update_submitted_qc>January 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

